Literature DB >> 2882686

The pancreatic-adrenocortical-pituitary clamp technique for study of counterregulation in humans.

P De Feo, G Perriello, M M Ventura, P Brunetti, F Santeusanio, J E Gerich, G B Bolli.   

Abstract

The present experiments were undertaken to develop an approach to analyze the contribution of individual glucose counterregulatory hormones in humans. For this purpose, 24 normal subjects were studied twice: once (control experiments) hypoglycemia was induced by subcutaneous infusion of insulin; and once [pancreatic-adrenocortical-pituitary (PAP) clamp technique] the spontaneous responses of plasma glucagon, growth hormone, and cortisol to hypoglycemia were prevented by intravenous somatostatin and oral metyrapone, respectively, and each hormone was infused at variable rates, which reproduced spontaneous changes in their circulating concentrations in the control experiments. Plasma glucose rate of decrease (0.052 +/- 0.003 vs. 0.06 +/- 0.003 mg X dl-1 X min-1), plasma glucose nadir (49.8 +/- 1.2 vs. 50 +/- 1.0 mg/dl), initial suppression of glucose production (0.22 +/- 0.01 vs. 0.23 +/- 0.01 mg X kg-1 X min-1), subsequent compensatory increase in glucose production (0.54 +/- 0.05 vs. 0.48 +/- 0.04 mg X kg-1 X min-1), and the increase in glucose utilization (0.45 +/- 0.05 vs. 0.42 +/- 0.05 mg X kg-1 X min-1) in PAP clamp and control experiments, respectively, were not significantly different and were significantly correlated. Changes in plasma alanine, lactate, free fatty acids, 3-beta-hydroxybutyrate concentrations were also virtually identical in the PAP clamp experiments and in control experiments. We conclude that the PAP clamp technique can faithfully reproduce the spontaneous hormonal and substrate responses to hypoglycemia and should be useful to assess the contribution of individual hormones during counterregulation by creating an isolated (total or partial) deficiency of a particular hormone without confounding compensatory changes in secretion of other counterregulatory hormones.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2882686     DOI: 10.1152/ajpendo.1987.252.4.E565

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning.

Authors:  G Perriello; P De Feo; E Torlone; C Fanelli; F Santeusanio; P Brunetti; G B Bolli
Journal:  Diabetologia       Date:  1990-01       Impact factor: 10.122

2.  Failure of substrate-induced gluconeogenesis to increase overall glucose appearance in normal humans. Demonstration of hepatic autoregulation without a change in plasma glucose concentration.

Authors:  T Jenssen; N Nurjhan; A Consoli; J E Gerich
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

3.  Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis.

Authors:  C G Fanelli; P De Feo; F Porcellati; G Perriello; E Torlone; F Santeusanio; P Brunetti; G B Bolli
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

4.  Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans.

Authors:  S Dinneen; A Alzaid; J Miles; R Rizza
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

5.  Decreased hepatic glucagon responses in type 1 (insulin-dependent) diabetes mellitus.

Authors:  L Orskov; K G Alberti; A Mengel; N Møller; O Pedersen; O Rasmussen; T Seefeldt; O Schmitz
Journal:  Diabetologia       Date:  1991-07       Impact factor: 10.122

6.  Inhibition of muscle glycogen synthase activity and non-oxidative glucose disposal during hypoglycaemia in normal man.

Authors:  L Orskov; J F Bak; O Schmitz; F Andreasen; E A Richter; C Skjaerbaek; N Møller
Journal:  Diabetologia       Date:  1996-02       Impact factor: 10.122

7.  Novel Insights Into Effects of Cortisol and Glucagon on Nocturnal Glucose Production in Type 2 Diabetes.

Authors:  Ananda Basu; Yogesh Yadav; Rickey E Carter; Rita Basu
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.